Logo

Bio-Techne

William Blair Initiates Coverage of Bio-Techne With Outperform Rating

The investment bank emphasized Bio-Techne's position in multiple high-growth and attractive end markets, including cell and gene therapy, spatial biology, and liquid biopsy.

Top Five Articles on GenomeWeb Last Week: Agilent, Bruker, Foundation Medicine, More

Last week, GenomeWeb's readers were most interested in Agilent Technologies announcing that it is discontinuing its Resolution Bioscience business.

Sylvester Comprehensive Cancer Center Wins $2.5M NCI Grant to Develop Prostate Cancer Test

The team will work with collaborators at Bio-Techne's Exosome Diagnostics to develop its prostate cancer biomarker on a new platform. 

Bio-Techne, Akoya End Partnership to Develop Automated Spatial Biology Workflow

The companies announced in 2022 that they would work to enable automated workflows for RNAscope tests on Akoya's spatial phenotyping systems.

'COVID Hangover' Subsiding, But China Uncertainty Remains for Bio-Techne
Premium

The company said on Tuesday that its fiscal fourth quarter revenues rose 5 percent and full-year 2023 revenues climbed 3 percent. 

Jul 14, 2023

In Brief This Week: DermTech, T2 Biosystems, Cofactor Genomics, Bio-Techne, Lunaphore, More

Jun 22, 2023

Bio-Techne to Acquire Swiss Spatial Biology Firm Lunaphore

Jun 5, 2023

Recent Data Boosts Clinical Utility Case for Exosome Diagnostics Prostate Cancer Test
Premium

May 19, 2023

New Products Posted to GenomeWeb: BD, Bio-Techne, PhenomeX, Deepcell, Ozette, Telesis Bio, More

May 12, 2023

New Products Posted to GenomeWeb: Bio-Techne, Grifols, Genome Insight, Genialis, Lucence

May 3, 2023

Bio-Techne Fiscal Q3 Revenues Tick Up 1 Percent as Firm Faces Macroeconomic Headwinds

Apr 17, 2023

Bio-Techne, Lunaphore Partner on Spatial Workflow Combining Protein and RNA Measurements

Apr 6, 2023

In Brief This Week: HTG Molecular Diagnostics, Indivumed, Bio-Techne, Shuwen Biotech, More

Mar 3, 2023

In Brief This Week: DermTech, Applied BioCode, Devyser, DiaSorin, Cytek, Bio-Techne, GenScript, More

Feb 24, 2023

National Government Services Expands Coverage for Bio-Techne's ExoDx Prostate Cancer Test

Jan 13, 2023

New Products Posted to GenomeWeb: Twist Bioscience, Centogene, Juno Diagnostics, Bio-Techne, More

Jan 12, 2023

JP Morgan Healthcare Conference, Day 3: Invitae, NanoString, Bio-Rad, Olink, More

Dec 21, 2022

Genomics Firms Tackle Carbon Emissions, Face Obstacles to Net-Zero Goals From Suppliers, Shipping
Premium

Dec 1, 2022

Oxford Nanopore Technologies, Bio-Techne Partner to Develop Carrier Screening Assay

Nov 18, 2022

In Brief This Week: 908 Devices, Natera, PerkinElmer, Hologic, Hamilton, BioFluidiX, More

Nov 1, 2022

Bio-Techne Fiscal Q1 Revenues Rise 5 Percent

Sep 26, 2022

Bio-Techne Files UK Patent Infringement Suit Against Molecular Instruments

Sep 9, 2022

In Brief This Week: Prenetics, MGI Tech, Strata Oncology, Mainz Biomed, Bio-Techne, More

Aug 19, 2022

New Products Posted to GenomeWeb: Qiagen, Boston Heart Diagnostics, Bio-Techne, More

Aug 4, 2022

Bio-Techne Hints at Future M&A Plans
Premium

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.